Cue Biopharma Q2 FY26 net loss widens to $153.07 million; revenue rises 162.61% to $7.88 million
CUE•Expenses increased sharply
Research and development expenses jumped to $49 million from $7.9 million, driven by CUE-221 licensing and one-time payments and non-cash charges.
General and administrative costs surged to $46.6 million from $3.7 million on one-time strategic transformation items, including $19.7 million in non-cash stock compensation.
Pipeline and regulatory updates
The company submitted an FDA IND for CUE-221 in food allergy.
It still expects Phase 2 CSU data by the end of Q3 and a CUE-401 Phase 1 start by year-end.
Q2 results show wider loss and higher revenue
Cue Biopharma posted a Q2 net loss of $153.1 million, widening from $8.5 million a year earlier.
Revenue rose to $7.9 million, more than doubled from on a preclinical milestone.
